273 related articles for article (PubMed ID: 35154471)
1. Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer.
Li W; Han Y; Sun C; Li X; Zheng J; Che J; Yao X; Kufe D
Theranostics; 2022; 12(3):999-1011. PubMed ID: 35154471
[TBL] [Abstract][Full Text] [Related]
2. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.
Rajabi H; Kufe D
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):117-122. PubMed ID: 28302417
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
Rajabi H; Alam M; Takahashi H; Kharbanda A; Guha M; Ahmad R; Kufe D
Oncogene; 2014 Mar; 33(13):1680-9. PubMed ID: 23584475
[TBL] [Abstract][Full Text] [Related]
4. Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications.
Khanbabaei H; Ebrahimi S; García-Rodríguez JL; Ghasemi Z; Pourghadamyari H; Mohammadi M; Kristensen LS
J Exp Clin Cancer Res; 2022 Sep; 41(1):278. PubMed ID: 36114510
[TBL] [Abstract][Full Text] [Related]
5. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D
Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899
[TBL] [Abstract][Full Text] [Related]
6. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
Oncogene; 2017 Nov; 36(46):6391-6407. PubMed ID: 28745318
[TBL] [Abstract][Full Text] [Related]
7. Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer.
Yamaguchi K; Yamamoto T; Chikuda J; Shirota T; Yamamoto Y
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204785
[TBL] [Abstract][Full Text] [Related]
8. Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer.
Chen Y; Lu L; Feng B; Han S; Cui S; Chu X; Chen L; Wang R
Oncotarget; 2017 May; 8(22):36787-36799. PubMed ID: 28415568
[TBL] [Abstract][Full Text] [Related]
9. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Nath S; Mukherjee P
Trends Mol Med; 2014 Jun; 20(6):332-42. PubMed ID: 24667139
[TBL] [Abstract][Full Text] [Related]
10. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
Hata T; Rajabi H; Yamamoto M; Jin C; Ahmad R; Zhang Y; Kui L; Li W; Yasumizu Y; Hong D; Miyo M; Hiraki M; Maeda T; Suzuki Y; Takahashi H; Samur M; Kufe D
Mol Cancer Ther; 2019 Oct; 18(10):1744-1754. PubMed ID: 31308076
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
12. miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1.
Wang X; Zhou X; Zeng F; Wu X; Li H
Breast Cancer; 2020 Jul; 27(4):765-775. PubMed ID: 32144736
[TBL] [Abstract][Full Text] [Related]
13. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.
Kufe DW
Oncogene; 2013 Feb; 32(9):1073-81. PubMed ID: 22580612
[TBL] [Abstract][Full Text] [Related]
14. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.
Roy LD; Sahraei M; Subramani DB; Besmer D; Nath S; Tinder TL; Bajaj E; Shanmugam K; Lee YY; Hwang SI; Gendler SJ; Mukherjee P
Oncogene; 2011 Mar; 30(12):1449-59. PubMed ID: 21102519
[TBL] [Abstract][Full Text] [Related]
15. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
[TBL] [Abstract][Full Text] [Related]
16. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
17. MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.
Alam M; Ahmad R; Rajabi H; Kufe D
Mol Cancer Res; 2015 Mar; 13(3):449-60. PubMed ID: 25368430
[TBL] [Abstract][Full Text] [Related]
18. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.
Ramasamy S; Duraisamy S; Barbashov S; Kawano T; Kharbanda S; Kufe D
Mol Cell; 2007 Sep; 27(6):992-1004. PubMed ID: 17889671
[TBL] [Abstract][Full Text] [Related]
19. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
[TBL] [Abstract][Full Text] [Related]
20. IGF-1-induced epithelial-mesenchymal transition in MCF-7 cells is mediated by MUC1.
Liao G; Wang M; Ou Y; Zhao Y
Cell Signal; 2014 Oct; 26(10):2131-7. PubMed ID: 24971507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
